Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The study is designed to test the hypothesis that the addition of a protease inhibitor to
dual NS5a-NS5B nucleoside prodrug analog will enhance antiviral efficacy and hence shorten
the treatment duration to 3 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Humanity & Healthy GI and Liver Centre Humanity and Health Research Centre